About Diagnostic Ventures
Unified by a mission—solving healthcare’s deadliest challenge.
Our story
Eliminating the wait for effective treatment.
Nearly one in three hospital deaths is linked to sepsis—a fast-moving condition where every hour without targeted treatment decreases survival by 8%. Within 12 hours, patients can face septic shock with a mortality rate of up to 50%. Yet traditional pathogen identification diagnostics take 12 to 48 hours.
Diagnostic Ventures licensed technology started in 2017 from research led by Dr. William Pitt and Dr. Richard Robison at Brigham Young University and supported by a 5 year $5.4M NIH grant. The team tackled bioengineering’s needle-in-a-haystack problem: isolating just 5–10 bacterial cells from billions of host cells.
The team engineered a proprietary centrifuge platform that isolates plasma in under four minutes. Working with BYU and Dr. Robison’s BSL-3 research facilities, Diagnostic Ventures is combining centrifugal isolation, downstream bacterial processing, Raman spectroscopy, and machine learning, targeting 98–99% pathogen identification accuracy.
Diagnostic Ventures holds exclusive license and patent rights supporting the platform and its development.
Our mission
Eliminate the wait for effective patient treatment.
Solving healthcare’s deadliest diagnostic challenges by pioneering advanced, rapid testing systems that eliminate the wait for effective patient treatment.
Our team
World-class scientists. Proven clinical leaders.
Built on a foundation of rigorous academic discovery and proven clinical execution, our team brings centuries of collective expertise to the frontline of medicine. We have turned our focus toward pioneering the advanced rapid diagnostics necessary to eradicate sepsis and redefine acute patient care.
Meet the teamMove faster with us
Partner with us.
Every minute counts when diagnosing sepsis. We are pioneering the world’s fastest comprehensive pathogen identification system to eliminate the wait for blood cultures and save lives. Reach out to learn more about our technology, clinical timeline, or partnership opportunities.
Contact us